These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 26403780)
1. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components. Lin TJ; Lin HT; Chang WT; Mitapalli S P; Hsiao PW; Yin SY; Yang NS Mol Cancer; 2015 Sep; 14():174. PubMed ID: 26403780 [TBL] [Abstract][Full Text] [Related]
2. Rapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based Vaccine. Lin TJ; Liang WM; Hsiao PW; M S P; Wei WC; Lin HT; Yin SY; Yang NS PLoS One; 2015; 10(10):e0138335. PubMed ID: 26426423 [TBL] [Abstract][Full Text] [Related]
3. Tumor cell lysates as immunogenic sources for cancer vaccine design. González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929 [TBL] [Abstract][Full Text] [Related]
4. Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines. Wen CC; Chen HM; Chen SS; Huang LT; Chang WT; Wei WC; Chou LC; Arulselvan P; Wu JB; Kuo SC; Yang NS J Biomed Sci; 2011 Jun; 18(1):44. PubMed ID: 21689407 [TBL] [Abstract][Full Text] [Related]
5. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656 [TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821 [TBL] [Abstract][Full Text] [Related]
7. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma. Aravindaram K; Wang PH; Yin SY; Yang NS Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790 [TBL] [Abstract][Full Text] [Related]
8. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Ren W; Strube R; Zhang X; Chen SY; Huang XF Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979 [TBL] [Abstract][Full Text] [Related]
9. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses. Dashti A; Ebrahimi M; Hadjati J; Memarnejadian A; Moazzeni SM Cancer Lett; 2016 Apr; 374(1):175-185. PubMed ID: 26803056 [TBL] [Abstract][Full Text] [Related]
10. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Aguilera R; Saffie C; Tittarelli A; González FE; Ramírez M; Reyes D; Pereda C; Hevia D; García T; Salazar L; Ferreira A; Hermoso M; Mendoza-Naranjo A; Ferrada C; Garrido P; López MN; Salazar-Onfray F Clin Cancer Res; 2011 Apr; 17(8):2474-83. PubMed ID: 21292818 [TBL] [Abstract][Full Text] [Related]
11. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Fang H; Ang B; Xu X; Huang X; Wu Y; Sun Y; Wang W; Li N; Cao X; Wan T Cell Mol Immunol; 2014 Mar; 11(2):150-9. PubMed ID: 24362470 [TBL] [Abstract][Full Text] [Related]
12. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716 [TBL] [Abstract][Full Text] [Related]
13. Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432. Ge C; Xing Y; Wang Q; Xiao W; Lu Y; Hu X; Gao Z; Xu M; Ma Y; Cao R; Liu J Int Immunopharmacol; 2011 Dec; 11(12):2200-7. PubMed ID: 22015603 [TBL] [Abstract][Full Text] [Related]
14. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316 [TBL] [Abstract][Full Text] [Related]
15. Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. Rojas-Sepúlveda D; Tittarelli A; Gleisner MA; Ávalos I; Pereda C; Gallegos I; González FE; López MN; Butte JM; Roa JC; Fluxá P; Salazar-Onfray F Cancer Immunol Immunother; 2018 Dec; 67(12):1897-1910. PubMed ID: 29600445 [TBL] [Abstract][Full Text] [Related]
16. 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity. Kim JH; Chen J; Majumder N; Lin H; Falo LD; You Z Gene Ther; 2005 Oct; 12(20):1517-25. PubMed ID: 16052205 [TBL] [Abstract][Full Text] [Related]
17. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity]. You J; Wang CL; Hao XS Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273 [TBL] [Abstract][Full Text] [Related]
18. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
19. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Fucikova J; Moserova I; Truxova I; Hermanova I; Vancurova I; Partlova S; Fialova A; Sojka L; Cartron PF; Houska M; Rob L; Bartunkova J; Spisek R Int J Cancer; 2014 Sep; 135(5):1165-77. PubMed ID: 24500981 [TBL] [Abstract][Full Text] [Related]
20. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70. Koide T; Iinuma H; Fukushima R Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]